Autolus Therapeutics plc
Autolus Therapeutics plc (AUTL): 12 pipeline candidates · ~12 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
12.3 months
D/E 3.84
Lead: Approved
12 candidates
N/A
N/A
A transparent, data-derived signal for Autolus Therapeutics plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$399.2M
Cash
$132.4M
Quarterly Burn
$65.3M
Runway
12.3 mo
Revenue
$26.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| aucatzyl | Approved |
| AUCATZYL/obe-cel | Phase 2 |
| auto1 | Phase 1/Phase 2 |
| AUTO1/22 | Phase 1/Phase 2 |
| AUTO4 | Phase 1/Phase 2 |
| AUTO5 | Phase 1/Phase 2 |
| AUTO6NG | Phase 1 |
| AUTO8 | Phase 1/Phase 2 |
| obe-cel | Phase 2 |
| Obe-cel (AUTO1) | Phase 2 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
82
Total value held
$155.6M
| Holder | Shares | Value |
|---|---|---|
| mak capital one llc | 33,621,487 | $46.4M |
| blackstone inc. | 20,485,611 | $28.3M |
| armistice capital, llc | 15,800,000 | $21.8M |
| tetragon partners gp ltd | 9,500,000 | $13.1M |
| schroder investment management group | 9,489,345 | $12.1M |
| bnp paribas asset management holding s.a. | 3,361,156 | $4.6M |
| laurion capital management lp | 3,316,626 | $4.6M |
| renaissance technologies llc | 2,299,499 | $3.2M |
| bank of america corp /de/ | 1,844,671 | $2.5M |
| blackrock, inc. | 1,480,732 | $2.0M |
Showing top 10 of 82 institutional holders of Autolus Therapeutics plc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Autolus Therapeutics plc's pipeline?
Autolus Therapeutics plc (AUTL) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Autolus Therapeutics plc's lead drug candidate?
Autolus Therapeutics plc's most advanced tracked candidate is aucatzyl (Approved) for adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia ("r/r B-ALL").
What is Autolus Therapeutics plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Autolus Therapeutics plc has approximately 12.3 months of cash runway.
What is Autolus Therapeutics plc's market capitalization?
Autolus Therapeutics plc's market capitalization is approximately $399.2M.
Who is the CEO of Autolus Therapeutics plc?
Dr. Christian Martin Itin Ph.D. is the chief executive officer of Autolus Therapeutics plc (AUTL).
Get the full picture on Autolus Therapeutics plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.